Sir
Sahakian and Morein-Zamir revive questions about the widespread availability and diversion of prescription medications for non-clinical use in healthy individuals (Nature 450, 1157–1159; 2007). Such questions drove legislators to impose controls a few decades ago, when amphetamines and barbiturates were widely available.
Because the diversion of drugs is linked to their availability, the World Health Organization monitors their production and consumption by individual nations. In the United States, production of stimulant drugs has soared during the past two decades, and enough are now produced each year for the daily treatment of at least four million individuals. Even though stimulants and other cognitive enhancers are intended for legitimate clinical use, history predicts that greater availability will lead to an increase in diversion, misuse and abuse. Among high-school students, abuse of prescription medications is second only to cannabis use.
Although access to medications that improve our cognitive performance might be desirable in theory, these may have adverse medical consequences. Some limitations are necesssary, for these medications can be addictive. This is because cognitive enhancers such as the stimulants methylphenidate (Ritalin) and amphetamine amplify the activity of dopamine, a neurotransmitter that increases saliency, making cognitive tasks and everyday activities seem more interesting and rewarding. This learned experience can lead to abuse of the drug and to compulsive use and addiction in vulnerable people.
As we increase our knowledge of how the brain works, we may one day have safe interventions to improve cognition. In the meantime, we need to learn from history and avoid using them unnecessarily.
Author information
Authors and Affiliations
Additional information
All Correspondence this week responds to Barbara Sahakian and Sharon Morein-Zamir's Commentary 'Professor's little helper' (Nature 450, 1157–1159; 2007) and the related discussion at http://network.nature.com/forums/naturenewsandopinion. This week, Nature launches an anonymous online survey to build on the informal questionnaire that the Commentary authors sent academics on the usage of brain-boosting drugs. In aggregate, the survey results will guide future editorial content on this topic. To take part, please visit: http://tinyurl.com/yq7nn3. Contributions to Correspondence may be submitted to correspondence@nature.com. Published contributions are edited. Readers are welcome to contribute to this discussion and many others at http://network.nature.com.
Rights and permissions
About this article
Cite this article
Volkow, N., Swanson, J. The action of enhancers can lead to addiction. Nature 451, 520 (2008). https://doi.org/10.1038/451520a
Published:
Issue Date:
DOI: https://doi.org/10.1038/451520a
This article is cited by
-
Locus coeruleus neuronal activity correlates with behavioral response to acute and chronic doses of methylphenidate (Ritalin) in adolescent rats
Journal of Neural Transmission (2017)
-
Ethically Justified, Clinically Applicable Criteria for Physician Decision-Making in Psychopharmacological Enhancement
Neuroethics (2009)